Progressive Supranuclear Palsy is a rare neurodegenerative disorder characterised by the presence of 4-repeat tau pathology. Progressive Supranuclear Palsy is regarded as a spectrum of different phenotypes characterised by predominant motor, cognitive, speech, or behavioural impairment. No therapy is available for this disease and symptomatic treatment offers only limited benefit. Sitilop is collaborating with Life Molecular Imaging and Invicro to evaluate tau depositions in Progressive Supranuclear Palsy using a novel tau PET tracer. The development of a selective tau radiotracer will provide an invaluable tool to understand the mechanisms and dynamics of tau accumulation, as well as to explore tau specific therapeutics, in Progressive Supranuclear Palsy.